Search Criteria: Research Area is "Neurobiology Research: Tet Expression System"
| Stock Number |
Strain Name Strain Description |
Standard Supply |
| 006965 | B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J | Repository- Live |
| Homozygotes are viable, fertile, normal in size and do not display any behavioral abnormalities. These targeted mutant mice have widespread expression of an optimized form of reverse tetracycline-controlled transactivator (rtTA-M2) protein. This R26-M2rtTA strain may be useful for doxycycline-inducible studies which utilize rtTA/tet-O (tet-on/TRE) models. | ||
| 007004 | B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ | Repository- Live |
| Transgenic mice expressing the tetracycline-controlled transactivator protein (tTA) under regulatory control of the forebrain-specific calcium-calmodulin-dependent kinase II (Camk2a) promoter are viable and fertile. When hemizygotes are mated to a second strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene can be blocked by administration of the tetracycline analog, doxycycline (dox). These mice are a "Tet-Off" tool that allow the inducible expression of genes in forebrain neurons, and may be useful in studying brain disorders such as Alzheimer's disease (when used in conjunction with Stock No. 005706, Stock No. 007049, Stock No. 007051, Stock No. 007052), Parkinson's
..... For more information please see the full descriiption on the strain data sheet | ||
| 005964 | B6.Cg-Tg(GFAP-tTA)110Pop/J | Repository- Live |
| Mice hemizygous for the transgene are viable fertile, normal in size and do not display any gross physical or behavioral abnormalities. These mice express a tetracycline-controlled transactivator protein (tTA) driven by the human glial fibrillary acidic protein (GFAP) promoter. When these mice are mated to a second transgenic strain that carries a target gene under the regulation of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in astrocytes in the bitransgenic offspring can be induced by withdrawal of the tetracycline analog, doxycycline. Doxycycline may be administered in the animals' water supply. This strain represents an effective tool for generating bitrangenic animals that may be useful to study inducible gene expression in the astrocytes of the central nervous system. | ||
| 007051 | B6.Cg-Tg(tetO-APPSwInd)102Dbo/J | Repository- Live |
| Hemizygotes for this tetO-APPswe/ind transgene are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP695) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APP695swe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the control of a tissue-specific promoter, APP695swe/ind expression in the appropriate tissues of the bitransgenic offspring can be regulated with the tetracycline analog doxycycline (dox). These tetO-APPswe/ind transgenic mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies. For example, when bred to a strain expressing tTA in brain tissues (see Stock No. For more information please see the full descriiption on the strain data sheet | ||
| 007052 | B6.Cg-Tg(tetO-APPSwInd)107Dbo/J | Repository- Live |
| Hemizygotes for this tetO-APPswe/ind transgene are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP695) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APP695swe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, APP695swe/ind expression in the target tissue of the bitransgenic offspring can be regulated with the tetracycline analog doxycycline (dox) in the resulting double mutant offspring.
These tetO-APPswe/ind transgenic mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies. For example, when bred to a strain expressing tTA in brain tissues (see Stock No.
..... | ||
| 007049 | B6.Cg-Tg(tetO-APPSwInd)885Dbo/J | Repository- Live |
| Hemizygotes for this tetO-APPswe/ind transgene are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP695) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APP695swe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, APP695swe/ind expression can be regulated in the appropriate tissue of the bitransgenic offspring with the tetracycline analog doxycycline (dox). These tetO-APPswe/ind transgenic mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies. For example, when bred to a strain expressing tTA in brain tissues (see Stock No. For more information please see the full descriiption on the strain data sheet | ||
| 003010 | B6;CBA-Tg(Camk2a-tTA)1Mmay/J | Repository- Live |
| Transgenic mice expressing the tetracycline-controlled transactivator protein (tTA) under regulatory control of the forebrain-specific calcium-calmodulin-dependent kinase II (Camk2a) promoter are viable, fertile, and display no overt phenotypic defects. Transgene expression can be blocked by the administration of the tetracycline analog doxycycline (dox) to the mice. Mating these transgenic mice to a second transgenic strain carrying a gene of interest coupled to a tetracycline-responsive promoter element (TRE; tetO) allows dox-inducible expression of the target gene specifically in forebrain neurons, and may be useful in studying brain disorders such as Alzheimer's disease (when used in conjunction with Stock No. 005706, Stock No. 007049, Stock No. 007051, Stock No. 00
..... For more information please see the full descriiption on the strain data sheet | ||
| 006004 | B6C3-Tg(tetO-APPSwInd)885Dbo/J | Repository- Live |
| Hemizygous mice are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APPswe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of tissue-specific promoters , APPswe/ind transgene expression can be regulated in the appropriate tissue of the bitransgenic offspring with the tetracycline analog, doxycycline. When bred to a strain expressing rtTA or tTA in brain tissues (see Stock No. 003010, for example), this mutant mouse strain may be useful in studies of Alzheimer's Disease. | ||
| 006618 | C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J | Repository- Live |
| Hemizygotes are viable and fertile. These transgenic mice express a mitochondrial-specific EYFP fusion protein under the control of a tetracycline-responsive promoter element (TRE;tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of tissue-specific promoter, tissue-specific expression of EYFP in mitochondria of the bitransgenic offspring can be regulated with the tetracycline analog, doxycycline. When bred to a strain expressing rtTA or tTA in forebrain neurons (see Stock No. 003010 for example), this mutant mouse strain may be useful in studies of neuronal mitochondrial dysfunction. | ||
| 008244 | FVB.Cg-Tg(tetO-cre)1Jaw/J | Repository- Live |
| Hemizygous transgenic mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express Cre recombinase under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the control of tissue-specific promoters, Cre recombinase expression and Cre-mediated recombination in the appropriate tissues of the bitransgenic offspring, can be regulated with the tetracycline analog, doxycycline. This strain represents an effective tool for generating inducible, tissue-specific-targeted mutants to study cell lineage during development. Importation of this model was supported by the Boomer Esiason Foundation. | ||
| 008168 | STOCK Tg(tetO-DTA)1Gfi/J | Repository- Live |
| These tet-DTA transgenic mice express diphtheria toxin A (DTA) under the control of a tetracycline operator (tetO; also called tetracycline-responsive element (TRE) or tet-operator) and a cytomegalovirus minimal promoter. When bred with another mouse expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA), tissue diphtheria toxin A expression can be regulated with the tetracycline analog doxycycline (dox) in the resulting double mutant offspring. These tet-DTA mice may be useful in generating bi-transgenic mutant mice for the reversible, inducible deletion of specific groups of cells. For example, when bred to a strain expressing tTA in cardiac myocytes (see Stock No. 003170 for example), this mutant mouse strain may be useful in studies of human cardiomyopathies. | ||
| 003767 | B6.Cg-Tg(Eno2tTA)5021Nes/J | Repository-Cryopreserved |
| These transgenic mice express the tetracycline-controlled activator protein (tTA) under the control of a rat neuron-specific enolase (Eno2) promoter. Although the Eno2 promoter has been shown to direct high levels of expression in brain tissue in general, this strain selectively expresses tTA at high levels in the striatum and cerebellum. When B6.Cg-Tg(Eno2tTA)5021Nes/J transgenic mice are mated to a second transgenic strain carrying a gene of interest under the regulation of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in the bitransgenic offspring may be induced in the tTA-expressing tissues by the withdrawal of the tetracycline analog, doxycycline (dox). For example, when these transgenic mice are bred with Stock No. 003762, a transgenic strain that expresses a Fosb variant under the direction of a TRE, the resulting bitransgenic offspring can be induced to express h
..... For more information please see the full descriiption on the strain data sheet | ||
| 003763 | B6.Cg-Tg(Eno2tTA)5030Nes/J | Repository-Cryopreserved |
| These transgenic mice express the tetracycline-controlled activator protein (tTA) under the control of a rat neuron-specific enolase (Eno2) promoter. Although the Eno2 promoter has been shown to direct high levels of expression in brain tissue in general, this strain selectively expresses tTA at high levels in the striatum and to a lesser extent in the cerebral cortex and hippocampus. When these transgenic mice are mated to a second transgenic strain carrying a gene of interest under the regulation of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in the bitransgenic offspring may be induced in the tTA-expressing tissues by the withdrawl of the tetracycline analog, doxycycline (dox). For example, when these transgenic mice are bred with Stock No. 003762, a transgenic strain that expresses a Fosb variant under the direction of a TRE, the resulting bitransgenic offspring ca
..... For more information please see the full descriiption on the strain data sheet | ||
| 008284 | B6.Cg-Tg(Scg2-tTA)1Jt/J | Repository-Cryopreserved |
| Homozygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These mice express tetracycline-controlled transactivator protein (tTA) under the control of a mouse secretogranin II promoter. When these mice are mated to a second transgenic strain that carries a gene of interest driven by a tetracycline-responsive promoter element (TRE; tetO), expression of that gene can be conditionally regulated by the presence or absence of doxycycline in the drinking water. Expression in the suprachiasmatic nucleus and brain of bitransgenic animals can be reversibly inhibited by the presence of doxycycline or induced by withdrawal of the tetracycline analog. | ||
| 005706 | C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J | Repository-Cryopreserved |
| Hemizygous transgenic mice are viable, fertile, normal in size and do not display any behavioral abnormalities. Mice homozygous for this transgene may not be viable. When these transgenic mice are bred with mice expressing the tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, expression of the CDK5R1/GFP fusion protein in the appropriate tissue of the bitransgenic offspring can be regulated by doxycycline administration. These mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies, amyotrophic lateral sclerosis (ALS), Niemann Pick Type C (NPC) disease, and Parkinson's disease.
Note: this transgenic strain was designed to breed with Tg(Camk2a-tTA) transgenic mice, (Stock No. 003010), a transgenic strain that expresses tTA in forebrain neurons. The resulting bitransgenic offspring exhibit the hallmark phenotype of Alzheimer's disease;
..... | ||
| 004127 | FVB-Tg(Nes-rtTA)306Rvs/J | Repository-Cryopreserved |
| Mice that are hemizygous for this transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat nestin intron II enhancer/promoter. According to the donating investigator, expression occurs in the neuroepithelium of the developing nervous system (embryonic days 10-17), in some neuron subsets of the adult mouse (e.g. cerebellum, hippocampal dentate gyrus, subventricular zone, spinal cord) and in adult testes. The rtTA gene is cotranscribed with the lacZ reporter gene Bgeo, which allows verification of the site of rtTA expression. When Tg(Nes-rtTA) hemizygous mice are mated to a second transgenic strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene may be regulated by the tetracycline analog, doxycycli
..... For more information please see the full descriiption on the strain data sheet | ||
| 005625 | FVB-Tg(Pcp2-tTA)3Horr/J | Repository-Cryopreserved |
| Mice that are homozygous for the transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. Cerebellar Purkinje cell-specific tTA expression has been confirmed using PCR. Constitutive expression of tTA in Purkinje cells makes this strain suitable for creating bitransgenic mice that can, by withdrawing tetracycline (or its derivative doxycycline), inducibly express a gene of interest in Purkinje cells when the gene of interest is under the direction of a tetracycline-responsive element (TRE; tetO). | ||
(17 stocks) Back to Top
How to Register Interest
Please indicate your interest in purchasing any of the strains listed below when they become available for distribution by checking the box next to the strain(s) of interest and then selecting the "Continue" button which leads to an Interest Form.View a Data sheet for New Strains Under Development
Select the strain name to link to the strain data sheet.
New Strains Under DevelopmentThe Jackson Laboratory serves as a worldwide distributor and national repository for common and rare strains of inbred mice and mice carrying spontaneous mutations or induced mutations (i.e., transgenic, targeted/"knockout", or chemically induced mutations). At any one time, we have over 100 strains at various stages of development and colony expansion. Strains "Under Development" fall into two categories depending on the anticipated demand from the scientific community.
- Receive periodic updates on the status of the colony UNDER DEVELOPMENT
- Obtain advance notification of strain availability and opportunity to order prior to the strain being published as available
- Provide input affecting speed and quantity of availability
It is VERY IMPORTANT that you register interest in strains Under Development. The anticipated demand for a strain enables us to determine effectively the distribution plan for each strain Under Development. Registering interest also provides benefits to you (including advance notification of pending availability). Whether a strain is made available from a live colony OR from our cryopreservation repository, you may want to consider the option of Dedicated Supply. To learn more about Dedicated Supply, go to Services.
- Strains that will be made available from a live distribution colony at The Jackson Laboratory.
These strains are designated as: "Under Development for Distribution Colony"- Strains that will be made available through the Cryopreservation Repository.
These strains are designated as: "Under Development for Cryopreservation Repository"
Send questions to our Technical Support team using the Express Technical Support Form.
(3.2)